TABLE 2.
MLST lineages, ST, gyrA mutations, and resistance phenotypes
| BURST lineage | Clonal complex | ST | Isolate | Year | gyrA mutationsa | Phenotypeb
|
|
|---|---|---|---|---|---|---|---|
| Ciprofloxacin | Nalidixic acid | ||||||
| Group 1 | 353 | 1036 | 83B | 2001 | His-81, Ser-119 | S | S |
| 104C | 2002 | His-81, Ser-119 | S | S | |||
| 116B | 2002 | His-81, Ser-119, Thr-86-Ile, Gly-110 | R | R | |||
| 65B | 2001 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| 48A | 2000 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| 48B | 2000 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| 65A | 2001 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| 65C | 2001 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| F19 | 2001 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| 118C | 2002 | His-81, Ser-119, Thr-86-Ile, Gly-110 | R | R | |||
| 82A | 2001 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| Unassigned | 1040 | 113B | 2002 | His-81, Ser-119, Thr-86-Ile | R | R | |
| 93A | 2001 | His-81, Ser-119 | S | S | |||
| 112A | 2002 | His-81, Ser-119, Thr-86-Ile | R | R | |||
| Group 2 | Unassigned | 1039 | 50C | 2000 | His-81, Ser-119 | S | S |
| 75A | 2001 | His-81, Ser-119 | S | S | |||
| 95B | 2001 | His-81, Ser-119 | S | S | |||
| 95A | 2001 | His-81, Ser-119 | R | R | |||
| 57A | 2001 | His-81, Ser-119 | S | S | |||
| 1041 | 62A | 2001 | His-81, Ser-119 | S | S | ||
| 64C | 2001 | His-81, Ser-119 | S | S | |||
| F18 | 2001 | His-81, Ser-119, Thr-86-Ala, Gly-110 | R | R | |||
| Group 3 | 22 | 1081 | 118B | 2002 | None | S | S |
| 660 | 118A | 2002 | None | S | S | ||
| 22 | 117C | 2002 | None | S | S | ||
| Group 4 | 354 | 1037 | 106B | 2002 | His-81, Ser-119, Thr-86-Ile | R | R |
| 1038 | 113A | 2002 | His-81, Ser-119 | S | S | ||
| 115B | 2002 | His-81, Ser-119 | S | S | |||
| V34A | 2002 | His-81, Ser-119 | S | S | |||
| Singleton STs | 52 | 52 | 44B | 2000 | His-81, Ser-119 | S | S |
| 47C | 2000 | His-81, Ser-119 | S | S | |||
| 72B | 2001 | His-81, Ser-119 | S | S | |||
| 55A | 2001 | His-81, Ser-119 | S | S | |||
| 257 | 824 | 103C | 2002 | His-81, Ser-119 | S | S | |
| 21 | 1359 | 90B | 2001 | His-81, Ser-119 | S | S | |
| 353 | 1211 | 115A | 2002 | His-81, Ser-119 | S | S | |
| 42 | 1370 | 41B | 2000 | His-81, Ser-119 | S | S | |
| Unassigned | 1358 | 84C | 2001 | His-81, Ser-119 | R | R | |
| 1035 | 130A | 2000 | His-81, Ser-119, Gly-110 | S | S | ||
| 76C | 2001 | His-81, Ser-119, Thr-86-Ala, Gly-110 | S | I | |||
| 110B | 2002 | His-81, Ser-119, Thr-86-Ile, Gly-110 | R | R | |||
| 76A | 2001 | His-81, Ser-119, Thr-86-Ala, Gly-110 | S | I | |||
| 76B | 2001 | His-81, Ser-119, Thr-86-Ala, Gly-110 | S | I | |||
| 78C | 2001 | His-81, Ser-119, Thr-86-Ala, Gly-110 | R | R | |||
| 78A | 2001 | His-81, Ser-119, Thr-86-Ala, Gly-110 | R | R | |||
| 110A | 2002 | His-81, Ser-119, Thr-86-Ile | R | R | |||
a
Silent mutations are His-81 (CAC→CAT), Ser-119 (AGT→AGC), and Gly-110 (GGC→GGT).
b
R, resistant; S, susceptible; I, intermediate.